A laryngologist explains the surprising causes of chronic throat clearing, including silent reflux, allergies and muscle memory. Learn expert strategies to break the cycle and protect vocal health.

Results of this phase III trial demonstrated that stapokibart rapidly, significantly, and sustainably controlled both nasal and ocular symptoms in patients with moderate-to-severe SAR, while markedly ...

A new CT-scan based risk score facilitates the identification of patients at risk of revision endoscopic sinus surgery due to chronic rhinosinusitis.

Analysts at Precedence Research expect the gene-editing market to grow 15.7% annually and reach $40.1 billion by 2034, ...

A new CT-scan based risk score facilitates the identification of patients at risk of revision endoscopic sinus surgery due to ...

Learn more about whether Corcept Therapeutics Incorporated or Novartis AG is a better investment based on AAII's A+ Investor ...

The following is a summary of "Real-world comparison of T2-biologics effectiveness in severe allergic asthma with nasal ...

The Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent (dupilumab) for the treatment of chronic obstructive pulmonary disease (COPD) in ...

Optinose (NASDAQ: OPTN) has announced its financial results for the year and quarter ending December 31, 2024, spotlighting ...

Dupixent approved as the first-ever biologic medicine in Japan for patients with COPDFollowing recent approvals in the EU, China, and the US, ...

In addition to COPD, Dupixent is approved in Japan in certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), prurigo nodularis and chronic spontaneous ...